![](https://www.ciotechoutlook.com/newsimages/special/6mx2zGt8.jpeg)
The biopharmaceutical business Gilead Sciences and Cognizant have extended their partnership for a further five years, with a total projected value of $800 million. This includes the renewal and growth of Cognizant's services.
In accordance with the deal, the NASDAQ-listed IT company will oversee projects to quicken Gilead's digital transformation as well as manage the pharmaceutical company's global IT infrastructure, platforms, apps, and advanced analytics. According to its exchange filing, this partnership will streamline several aspects of Gilead's operations with the aim of reducing the time it takes for different drugs to treat serious illnesses including HIV, viral hepatitis, and cancer to reach the market.
Gilead and Cognizant have been working together for more than three years to embrace technologies created for business operations, new product launches, and optimizing IT processes for research, production, and commercialization of its goods.
To enhance Gilead's customer service and help it achieve greater manufacturing efficiencies, Cognizant proposes to deploy Generative Artificial Intelligence (GenAI) and AI automation.
"The GenAI advances should enable Gilead to provide greater visibility and transparency about the company’s treatments to patients and internal employees globally. Gilead will leverage Cognizant’s Neuro IT service for AI automation innovation, which should help Gilead to bring products to market more efficiently," the release added.
"Working together our teams will be leveraging the latest technologies from automation to cloud computing, and Generative AI to help Gilead bring its products to market faster, more efficiently, and with higher customer satisfaction," said said Surya Gummadi, executive vice president and president of Cognizant Americas.
Over the past few weeks, the large IT services companies have been constantly announcing significant transactions. A $2 billion AI-led transaction with an existing client, stretched over five years, was disclosed by Infosys last week.